Mild–moderate sedation, initial risk of activation and akathisia, low risk of dose-dependent EPS, low risk of metabolic syndrome, high risk of QTc prolongation, low risk of hyperprolactinaemia Mild–moderate sedation, risk of initial postural hypotension, low risk of dose-dependent EPS, high risk of hyperprolactinaemiaĪpproximately 11 days (steady state occurs after 4 x 2-weekly injections) Sedative and tranquillising, low risk of EPS, low risk of hyperprolactinaemia, moderate–high risk of weight gain and metabolic syndrome, anticholinergicĭrug effects longer lasting so used once daily Moderately sedative and tranquillising, moderate risk of dose-dependent EPSħ hours, first active metabolite norquetiapine 12 hours Low risk of sedation, low risk of dose-dependent EPS, high risk of hyperprolactinaemia Mildly sedative, low risk of metabolic syndrome, low–moderate risk of dose-dependent EPS, low– moderate risk of hyperprolactinaemia, low risk of QTc prolongation, nausea Moderately sedative and tranquillising, high risk of weight gain and metabolic syndrome, moderately anticholinergic, low risk of hyperprolactinaemia High risk of EPS, hyperprolactinaemia, low risk of metabolic syndrome Moderate–high risk of EPS, moderate risk of metabolic syndrome, hyperprolactinaemia Sedative, anticholinergic, postural hypotension, paralytic ileus, agranulocytosis, convulsions, high risk of metabolic syndrome, cardiac effects, nocturnal hypersalivation, urinary incontinence Sedative and tranquillising, anticholinergic, moderate risk of EPS, postural hypotension, photosensitivity, moderate risk of metabolic syndrome, hyperprolactinaemia
Initially activating with possible akathisia, low sedation, low risk of metabolic syndrome Mildly sedative, dose-dependent EPS, low–moderate risk of metabolic syndrome Initially activating, initial akathisia risk, low sedation, low risk of metabolic syndrome, very low risk of increasing prolactin Low sedation risk, can be activating, dose-dependent EPS, hyperprolactinaemia, low risk of metabolic syndrome, high risk QTc prolongation (very dangerous in overdose) doi:10.1097/WNF.Table 1 - Antipsychotic drugs available in Australia Assessing and reporting the adverse effects of antipsychotic medication: A systematic review of clinical studies, and prospective, retrospective, and cross-sectional research. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. doi:10.1016/j.pnpbp.2012.05.011īloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. Progress in Neuro-Psychopharmacology and Biological Psychiatry. Symptom structure of antipsychotic-induced obsessive compulsive symptoms in schizophrenia patients. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. doi:10.4103/psychiatry.IndianJPsychiatry_519_18ĭold M, Aigner M, Lanzenberger R, Kasper S. Antipsychotic augmentation in the treatment of obsessive-compulsive disorder. Obsessive-compulsive disorder (OCD): Practical strategies for pharmacological and somatic treatment in adults.
Treatment non-response in OCD: methodological issues and operational definitions. Pallanti S, Hollander E, Bienstock C, et al. The Yale-Brown Obsessive Compulsive Scale. Goodman WK, Price LH, Rasmussen SA, et al. Psychopharmacological treatment of obsessive-compulsive disorder (OCD).
Mindfulness-based cognitive therapy (MBCT) in patients with obsessive-compulsive disorder (OCD) and residual symptoms after cognitive behavioral therapy (CBT): a randomized controlled trial. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB, American Psychiatric Association. Pharmacological treatment of obsessive-compulsive disorder.
0 kommentar(er)
